IMPACT is a 12-week accelerator program that aims to advance early-stage medical device and biotech companies who have been impacted by the pandemic and/or are addressing key health security challenges. Up to 10 startups will be selected for the cohort and will go through a series of educational workshops, mentorship and more.

IMPACT participants will pitch their innovation to a panel of investors and have the opportunity for one-on-one follow-on meetings. University spin-outs are welcomed and encouraged to apply. The IMPACT Program is being sponsored by Amgen, Asahi Intecc, BARDA DRIVe, Boston Scientific, Hologic, Johnson & Johnson Innovation and Sarepta Therapeutics. 

The application for cycle 3 will be open from February 22nd through March 22nd. This cycle will be centric to Hologic’s Areas of Technology Interest:

• Devices intended to simplify and improve therapeutic procedures in the women’s health space, filling treatment gaps and advancing patient care. Areas of interest include:
  • GYN transvaginal procedures, such as:
    • Tubal obstruction (HSG, selective HSG)
    • Biopsy collection
    • Vaginal Surgery
  • GYN Laparoscopic surgery
  • Pelvic organ prolapse
  • Pelvic/bladder health 
  • Contraception (non-hormonal)
  • Fertility
  • Oncology solutions
  • Surgical approaches to oncology

Any questions may be directed to brennan_fournier@uml.edu or richard_meiklejohn@uml.edu

Apply here!